MedTrace Logo

Fluorescence Guided Surgery in Breast Cancer

NCT02583568 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-02-13

No results posted yet for this study

Summary

A need for further investigation for fluorescence image-guided surgery in breast conserving surgery (BCS) has arisen following the results obtained from a phase I feasibility breast cancer trial (BIRDYE study: ABR NL 37479.042011). The aim of this study is to define the optimal dose of the fluorescent tracer Bevacizumab-IRDye800CW for intraoperative delineation of breast cancer tissue using the improved and optimized fluorescent tracer and camera system.

Conditions

Interventions

DRUG

Bevacizumab-800CW

three days prior to surgery bevacizumab-800CW will be administered

Sponsors & Collaborators

  • Martini Hospital Groningen

    collaborator OTHER

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • G.M van Dam, prof. dr. · UMCG

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-01-31
Completion
2017-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02583568 on ClinicalTrials.gov